AbbVie (ABBV) Income from Continuing Operations (2012 - 2026)

AbbVie (ABBV) has reported Income from Continuing Operations for 15 consecutive years, with $3.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Income from Continuing Operations rose 284.27% year-over-year to $3.6 billion in Q2 2026; TTM through Jun 2026 was $6.3 billion, a 67.49% increase from a year earlier, with the FY2025 full-year figure at $4.2 billion, down 1.24% from the prior year.
• Income from Continuing Operations was $3.6 billion for Q2 2026 at AbbVie, up from $697.0 million in the prior quarter.
• Over five years, Income from Continuing Operations peaked at $4.5 billion in Q1 2022 and troughed at -$97.0 million in Q1 2023.
• A 5-year average of $1.6 billion and a median of $1.4 billion in 2024 frame the typical range for Income from Continuing Operations.
• Across the five-year window, Income from Continuing Operations plunged 102.79% in 2024 and jumped 7991.3% in 2025, its largest moves.
• Over 5 years, Income from Continuing Operations stood at $2.5 billion in 2022, then slumped by 66.67% to $824.0 million in 2023, then sank by 102.79% to -$23.0 million in 2024, then jumped by 7991.3% to $1.8 billion in 2025, then soared by 99.23% to $3.6 billion in 2026.
• The last three Income from Continuing Operations figures came in at $3.6 billion (Q2 2026), $697.0 million (Q1 2026), and $1.8 billion (Q4 2025), per Business Quant data.